This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
infectious diseases | 972 |
infectious disease | 540 |
infectious bronchitis | 308 |
public health | 293 |
bronchitis virus | 222 |
united states | 194 |
emerging infectious | 134 |
sir model | 108 |
pediatric infectious | 85 |
mg ml | 80 |
avian infectious | 79 |
infectious waste | 78 |
staphylococcus aureus | 78 |
infectious agents | 76 |
disease emergence | 71 |
respiratory tract | 66 |
highly infectious | 65 |
th century | 64 |
escherichia coli | 61 |
ebola virus | 59 |
respiratory syndrome | 58 |
mg kg | 57 |
west nile | 57 |
human infectious | 57 |
acute respiratory | 54 |
health care | 53 |
risk factors | 52 |
fuzzy logic | 51 |
early warning | 51 |
hiv aids | 49 |
developing countries | 49 |
waste materials | 48 |
infectious agent | 47 |
new york | 47 |
surveillance data | 46 |
intensive care | 45 |
infectious remains | 45 |
dengue fever | 45 |
stem cell | 45 |
severe acute | 44 |
antimicrobial resistance | 43 |
incubation period | 43 |
disease control | 43 |
disease surveillance | 43 |
johns hopkins | 43 |
global health | 42 |
immune response | 42 |
doc id | 41 |
cord uid | 41 |
climate change | 40 |
blood cultures | 40 |
nile virus | 39 |
virus infection | 39 |
antibiotic resistance | 38 |
cell transplantation | 38 |
world health | 38 |
hdc asct | 37 |
disease transmission | 37 |
human health | 37 |
streptococcus pneumoniae | 36 |
ibv strains | 35 |
disease outbreaks | 34 |
time series | 34 |
clinical isolates | 34 |
health organization | 34 |
control measures | 33 |
surveillance system | 32 |
virus disease | 31 |
zoonotic disease | 30 |
resistant strains | 30 |
emerging diseases | 29 |
avian influenza | 29 |
fatality rate | 29 |
resistant bacteria | 29 |
hopkins data | 29 |
emerging infections | 29 |
communicable diseases | 28 |
tract infections | 28 |
pseudomonas aeruginosa | 28 |
urinary tract | 28 |
million people | 28 |
scarlet fever | 27 |
drug resistance | 26 |
zoonotic diseases | 26 |
agar dilution | 26 |
fuzzy inference | 26 |
disease risk | 26 |
environmental factors | 26 |
per year | 26 |
immune responses | 26 |
confirmed cases | 26 |
medical institutions | 26 |
antimicrobial agents | 25 |
transmission rate | 25 |
tract infection | 25 |
disease specialists | 25 |
strains isolated | 25 |
infection control | 25 |
viral load | 25 |
internal medicine | 25 |
nucleic acid | 24 |
developing world | 24 |
emerging pathogens | 24 |
susceptibility testing | 24 |
tropical diseases | 24 |
following flooding | 24 |
human disease | 24 |
human population | 24 |
ibv infection | 24 |
high risk | 23 |
nosocomial infections | 23 |
hiv infection | 23 |
dhinakar raj | 23 |
borne diseases | 23 |
land use | 23 |
model parameters | 23 |
case fatality | 23 |
waste management | 22 |
york city | 22 |
raj jones | 22 |
inference system | 22 |
reproduction number | 22 |
infectious uveitis | 22 |
hematopoietic stem | 22 |
one hundred | 21 |
bactericidal activity | 21 |
immune system | 21 |
data analysis | 21 |
university hospital | 21 |
food production | 21 |
care unit | 20 |
vitro activity | 20 |
ibv strain | 20 |
respiratory infections | 20 |
medical microbiology | 20 |
antibiotic use | 20 |
influenza virus | 20 |
one case | 20 |
risk communication | 20 |
data collection | 20 |
st century | 20 |
global burden | 20 |
bacterial infections | 20 |
dilution method | 19 |
infectious diarrhea | 19 |
clostridium difficile | 19 |
middle east | 19 |
population size | 19 |
epithelial cells | 19 |
hbv dna | 19 |
resistant staphylococcus | 19 |
antibiotic therapy | 19 |
human pathogens | 19 |
harderian gland | 18 |
mic mg | 18 |
egg production | 18 |
lyme disease | 18 |
chickens infected | 18 |
confirmed highly | 18 |
disease epidemiology | 18 |
hemorrhagic fever | 18 |
many infectious | 18 |
space model | 18 |
th day | 17 |
saharan africa | 17 |
diseases working | 17 |
zika virus | 17 |
disease outbreak | 17 |
american pediatric | 17 |
antibiotic treatment | 17 |
drug resistant | 17 |
working party | 17 |
typhoid fever | 17 |
basic reproduction | 17 |
otitis media | 17 |
klebsiella pneumoniae | 17 |
health surveillance | 17 |
resistance rates | 16 |
antimicrobial therapy | 16 |
haemophilus influenzae | 16 |
respiratory disease | 16 |
two groups | 16 |
medical school | 16 |
five patients | 16 |
five years | 16 |
disease data | 16 |
surveillance systems | 16 |
economic development | 16 |
herd immunity | 16 |
russian federation | 16 |
microbial threats | 16 |
dynamic system | 16 |
susceptible host | 16 |
ibv replication | 16 |
significantly higher | 16 |
social distancing | 16 |
clinical microbiology | 16 |
commonly used | 16 |
diarrheal diseases | 16 |
side effects | 16 |
control group | 16 |
systematic review | 16 |
billion people | 16 |
mean age | 15 |
two patients | 15 |
hcv rna | 15 |
drinking water | 15 |
organ cultures | 15 |
infection dynamics | 15 |
total number | 15 |
seir model | 15 |
antiretroviral therapy | 15 |
west africa | 15 |
chain reaction | 15 |
copies ml | 15 |
disease ecology | 15 |
three patients | 15 |
past years | 15 |
disease incidence | 15 |
immunocompromised patients | 15 |
mortality rate | 15 |
german society | 15 |
pediatric society | 15 |
environmental change | 15 |
adaptive immune | 15 |
results obtained | 15 |
infected patients | 15 |
lower respiratory | 15 |
clinical strains | 15 |
ebola outbreak | 15 |
yellow fever | 15 |
last years | 15 |
one patient | 15 |
agricultural development | 15 |
human populations | 15 |
disease agents | 15 |
times higher | 15 |
polymerase chain | 15 |
medical care | 15 |
general hospital | 15 |
aedes aegypti | 15 |
antimicrobial susceptibility | 15 |
death rate | 15 |
infected individuals | 15 |
neutropenic patients | 15 |
may also | 15 |
years ago | 14 |
conclusion reached | 14 |
risk assessment | 14 |
murine typhus | 14 |
resistance genes | 14 |
clinical trials | 14 |
teaching hospital | 14 |
population growth | 14 |
risk factor | 14 |
north america | 14 |
large number | 14 |
fungal infections | 14 |
health department | 14 |
available data | 14 |
helicobacter pylori | 14 |
national institute | 14 |
haemorrhagic fever | 14 |
diffusion method | 14 |
disease prevention | 14 |
autologous stem | 14 |
active surveillance | 14 |
significant differences | 14 |
following exposure | 14 |
viral hepatitis | 14 |
east respiratory | 14 |
two cases | 14 |
transplant recipients | 14 |
coli strains | 14 |
newly emerging | 14 |
peripheral blood | 14 |
human transmission | 13 |
health infrastructure | 13 |
mycobacterium tuberculosis | 13 |
prospective study | 13 |
invasive fungal | 13 |
global trends | 13 |
influenza pandemic | 13 |
health interventions | 13 |
reproductive tract | 13 |
disk diffusion | 13 |
index case | 13 |
medical examiners | 13 |
health policy | 13 |
basic sir | 13 |
candida species | 13 |
blood samples | 13 |
air travel | 13 |
south africa | 13 |
herpes zoster | 13 |
febrile neutropenia | 13 |
heart disease | 13 |
well tolerated | 13 |
hospitalized patients | 13 |
risks perceived | 13 |
vector control | 13 |
live attenuated | 13 |
increased risk | 13 |
age group | 13 |
host population | 13 |
emerging disease | 13 |
hong kong | 13 |
global scale | 12 |
dengue virus | 12 |
statistical modelling | 12 |
fatality rates | 12 |
infection fatality | 12 |
immune deficiency | 12 |
cancer patients | 12 |
nipah virus | 12 |
rheumatic fever | 12 |
clavulanic acid | 12 |
copyright holder | 12 |
human beings | 12 |
clinical signs | 12 |
waste disposal | 12 |
four types | 12 |
united kingdom | 12 |
present study | 12 |
human immunodeficiency | 12 |
immunodeficiency virus | 12 |
underlying disease | 12 |
nitric oxide | 12 |
mortality rates | 12 |
every year | 12 |
pathogen transmission | 12 |
nccls guidelines | 12 |
patients infected | 12 |
reported cases | 12 |
world war | 12 |
important role | 12 |
soft tissue | 12 |
case study | 12 |
literature review | 12 |
pulmonary cases | 12 |
international license | 12 |
diseases following | 12 |
school children | 12 |
disease diagnosis | 12 |
clinical manifestations | 12 |
neural network | 12 |
imported infectious | 12 |
different strains | 12 |
acute diarrhea | 12 |
vaccine development | 12 |
performance evaluation | 12 |
heavy rainfall | 12 |
viral infections | 12 |
high mortality | 12 |
first time | 12 |
medical oncology | 12 |
reproductive number | 12 |
made available | 12 |
agricultural expansion | 12 |
susceptible individuals | 12 |
emerging pathogen | 12 |
acute infectious | 11 |
age groups | 11 |
drug use | 11 |
major cause | 11 |
vector population | 11 |
health departments | 11 |
natural disasters | 11 |
biological weapons | 11 |
medical waste | 11 |
infected chickens | 11 |
jakob disease | 11 |
patients undergoing | 11 |
health impacts | 11 |
streptococcus pyogenes | 11 |
middle ear | 11 |
ecological systems | 11 |
rift valley | 11 |
retrospective study | 11 |
diseases will | 11 |
routine data | 11 |
precritical terrain | 11 |
diversity patterns | 11 |
herpes simplex | 11 |
fuzzy cognitive | 11 |
reemerging infectious | 11 |
threshold value | 11 |
recovery rate | 11 |
travel history | 11 |
compartment model | 11 |
epidemic diseases | 11 |
young children | 11 |
valley fever | 11 |
blood culture | 11 |
life expectancy | 11 |
directly observed | 11 |
statistical models | 11 |
disease management | 11 |
international travel | 11 |
high level | 11 |
six patients | 11 |
agricultural intensification | 11 |
population density | 11 |
disease models | 11 |
study showed | 11 |
resistant isolates | 11 |
influenza viruses | 11 |
digestive tract | 11 |
modelling approach | 11 |
year period | 11 |
outbreak investigation | 11 |
sustainable development | 11 |
innate immune | 11 |
body fluids | 11 |
united nations | 11 |
first five | 11 |
medical university | 11 |
mechanistic model | 11 |
diseases among | 11 |
cell transplant | 11 |
autologous hematopoietic | 11 |
adverse events | 11 |
long term | 11 |
mechanistic models | 11 |
new infectious | 11 |
negative bacteria | 11 |
susceptible strains | 11 |
gel electrophoresis | 11 |
bacillus anthracis | 11 |
fuzzy techniques | 11 |
tract infectious | 10 |
given time | 10 |
war ii | 10 |
healthy volunteers | 10 |
compartment models | 10 |
observation effort | 10 |
medical center | 10 |
also used | 10 |
drug administration | 10 |
methods used | 10 |
disposal law | 10 |
health professionals | 10 |
zoonotic pathogens | 10 |
international health | 10 |
global climate | 10 |
clinical trial | 10 |
reemerging diseases | 10 |
preventive measures | 10 |
national security | 10 |
control study | 10 |
logic techniques | 10 |
infectious materials | 10 |
outbreak investigations | 10 |
even though | 10 |
among patients | 10 |
tissue concentration | 10 |
creative commons | 10 |
early th | 10 |
posted may | 10 |
version posted | 10 |
time period | 10 |
bloodstream infections | 10 |
methicillin resistant | 10 |
granted medrxiv | 10 |
case definitions | 10 |
surgeon general | 10 |
ib vaccination | 10 |
significant difference | 10 |
food safety | 10 |
will help | 10 |
vaccination strategies | 10 |
tuberculosis cases | 10 |
blood agar | 10 |
least one | 10 |
systematic literature | 10 |
results showed | 10 |
human services | 10 |
differential equations | 10 |
viral replication | 10 |
borne disease | 10 |
will also | 10 |
times per | 10 |
local health | 10 |
etiologic agent | 10 |
new pathogens | 10 |
spectrum beta | 10 |
expected number | 10 |
mathematical models | 10 |
statistical model | 10 |
antifungal agents | 10 |
children aged | 10 |
high rate | 10 |
patients received | 10 |
type i | 10 |
author funder | 10 |
bloodstream infection | 10 |
infant mortality | 10 |
health systems | 10 |
direct contact | 10 |
upper respiratory | 10 |
two hundred | 10 |
mathematical modelling | 10 |
neglected tropical | 10 |
disease threats | 10 |
dengue cases | 10 |
islamic republic | 10 |
personal protective | 10 |
economic impact | 10 |
removed compartment | 10 |
aureus strains | 10 |
global threat | 10 |
parasitic diseases | 10 |
disease specialist | 9 |
tracheal organ | 9 |
ib vaccines | 9 |
president obama | 9 |
pulmonary tuberculosis | 9 |
examples include | 9 |
antifungal therapy | 9 |
specific disease | 9 |
health information | 9 |
resistant organisms | 9 |
serological tests | 9 |
previously unknown | 9 |
cfu ml | 9 |
acute bronchitis | 9 |
eight patients | 9 |
pandemic influenza | 9 |
disease distributions | 9 |
nobel prize | 9 |
based fuzzy | 9 |
per day | 9 |
agricultural production | 9 |
disease virus | 9 |
enterococcus spp | 9 |
generation cephalosporins | 9 |
based approach | 9 |
medical attention | 9 |
adverse effects | 9 |
milk supply | 9 |
mortality associated | 9 |
ambali jones | 9 |
avian coronavirus | 9 |
disease research | 9 |
esair model | 9 |
serum concentrations | 9 |
syndrome coronavirus | 9 |
positive bacteria | 9 |
geographic distribution | 9 |
piperacillin tazobactam | 9 |
major causes | 9 |
lassa fever | 9 |
core antigen | 9 |
patients hospitalized | 9 |
summer diarrhea | 9 |
widely used | 9 |
infectious diarrheas | 9 |
antibacterial activity | 9 |
mg dl | 9 |
infectious cases | 9 |
university medical | 9 |
infection caused | 9 |
antiretroviral drugs | 9 |
world population | 9 |
early diagnosis | 9 |
wastewater treatment | 9 |
total population | 9 |
whooping cough | 9 |
logic methods | 9 |
health authorities | 9 |
risk management | 9 |
infectious period | 9 |
collect data | 9 |
pesticide use | 9 |
lymphoid tissue | 9 |
severe sepsis | 9 |
seven patients | 9 |
managed care | 9 |
medical institution | 9 |
different types | 9 |
may lead | 9 |
pneumoniae isolates | 9 |
variant creutzfeldt | 9 |
effective reproductive | 9 |
resistant enterobacteriaceae | 9 |
health problem | 9 |
may result | 9 |
critical terrain | 9 |
care units | 9 |
broiler chickens | 9 |
study group | 9 |
chronic diseases | 9 |
simplex virus | 9 |
hcv core | 9 |
protective equipment | 9 |
antibody response | 9 |
paratyphoid fever | 9 |
experimentally infected | 9 |
medical department | 9 |
czech republic | 9 |
systematic analysis | 9 |
respiratory infectious | 9 |
determined using | 9 |
population dynamics | 9 |
vibrio cholerae | 9 |
leading cause | 9 |
use change | 9 |
flood events | 9 |
two different | 9 |
statistical analysis | 9 |
global public | 8 |
reservoir host | 8 |
ice cream | 8 |
well known | 8 |
wide range | 8 |
type ifns | 8 |
environmental conditions | 8 |
disease dynamics | 8 |
day rule | 8 |
water supply | 8 |
laying hens | 8 |
associated diarrhea | 8 |
different countries | 8 |
spike protein | 8 |
global response | 8 |
control programs | 8 |
amino acid | 8 |
program evaluation | 8 |
naturally occurring | 8 |
reverse transcriptase | 8 |
controlled trial | 8 |
ecological factors | 8 |
cognitive map | 8 |
susceptible compartment | 8 |
cerebrospinal fluid | 8 |
income countries | 8 |
disease systems | 8 |
industrialized countries | 8 |
inbred lines | 8 |
patients treated | 8 |
hidden model | 8 |
new diseases | 8 |
meningococcal meningitis | 8 |
extended spectrum | 8 |
agar plates | 8 |
emerging human | 8 |
waterborne disease | 8 |
opportunistic infections | 8 |
bacteria isolated | 8 |
active pulmonary | 8 |
vector populations | 8 |
stochastic sir | 8 |
viral infection | 8 |
disease caused | 8 |
new opportunities | 8 |
disease occurrence | 8 |
clinical symptoms | 8 |
disc diffusion | 8 |
contagious individuals | 8 |
information systems | 8 |
three cases | 8 |
dengue hemorrhagic | 8 |
ibv infections | 8 |
latin america | 8 |
gives rise | 8 |
health risks | 8 |
barr virus | 8 |
negative rods | 8 |
early detection | 8 |
results suggest | 8 |
determine whether | 8 |
acquired pneumonia | 8 |
synergy test | 8 |
minimum inhibitory | 8 |
see also | 8 |
disease model | 8 |
statistically significant | 8 |
resistance rate | 8 |
disease study | 8 |
health concern | 8 |
suspected highly | 8 |
animal health | 8 |
causative agent | 8 |
versus cmd | 8 |
bacterial infection | 8 |
mathematical model | 8 |
giving rise | 8 |
infection rates | 8 |
disease vectors | 8 |
revised regulation | 8 |
supplementary material | 8 |
materials disposed | 8 |
sheep blood | 8 |
exponential outbreak | 8 |
data sources | 8 |
clinical cure | 8 |
among children | 8 |
waste workers | 8 |
observed data | 8 |
statistical methods | 8 |
shock syndrome | 8 |
infectious complications | 8 |
clean water | 8 |
new antibiotics | 8 |
new infections | 8 |
one day | 8 |
new confirmed | 8 |
domesticated animals | 8 |
recent years | 8 |
bone marrow | 8 |
sexually transmitted | 8 |
acquired infection | 8 |
better understanding | 8 |
cystic fibrosis | 8 |
candida spp | 8 |
presidential address | 8 |
bronchitis viruses | 8 |
food animals | 8 |
virus infections | 8 |
cause disease | 8 |
expert system | 8 |
antibiotic concentrations | 8 |
following ibv | 8 |
human host | 8 |
sharp objects | 8 |
resistance phenotypes | 8 |
diabetes mellitus | 8 |
may cause | 8 |
severe disease | 8 |
preventable diseases | 8 |
factors associated | 8 |
bordetella pertussis | 8 |
coli isolates | 8 |
disease risks | 8 |
chikungunya virus | 8 |
health officials | 7 |
variant strain | 7 |
clinical data | 7 |
klebsiella spp | 7 |
children attending | 7 |
may occur | 7 |
microdilution method | 7 |
many factors | 7 |
human cases | 7 |
resistance mutations | 7 |
succeeding text | 7 |
lactam antibiotics | 7 |
also important | 7 |
entire population | 7 |
multiple sclerosis | 7 |
laying chickens | 7 |
three times | 7 |
may increase | 7 |
using fuzzy | 7 |
enterococcus sp | 7 |
salmonella spp | 7 |
antibiotic susceptibility | 7 |
took place | 7 |
enteric bacteria | 7 |
infecting ibv | 7 |
early phase | 7 |
pg ml | 7 |
eight cases | 7 |
health threats | 7 |
outbreaks following | 7 |
pregnant women | 7 |
new era | 7 |
line therapy | 7 |
months later | 7 |
late th | 7 |
one health | 7 |
geographical area | 7 |
hospital stay | 7 |
supportive care | 7 |
natural history | 7 |
three years | 7 |
chronic hepatitis | 7 |
th cells | 7 |
geographic distributions | 7 |
essential oils | 7 |
control strategies | 7 |
quinupristin dalfopristin | 7 |
reduced susceptibility | 7 |
hepatocellular carcinoma | 7 |
antimicrobial use | 7 |
disease spread | 7 |
least squares | 7 |
dna sequencing | 7 |
method according | 7 |
nephropathogenic ibv | 7 |
infectious wastes | 7 |
per person | 7 |
enteric pathogens | 7 |
environmental determinants | 7 |
surveillance program | 7 |
diseases infectious | 7 |
aids patients | 7 |
fusidic acid | 7 |
kg day | 7 |
second group | 7 |
chronic infections | 7 |
neonatal sepsis | 7 |
high resistance | 7 |
million deaths | 7 |
measles outbreak | 7 |
bacterial resistance | 7 |
biosafety level | 7 |
stochastic epidemic | 7 |
virus isolated | 7 |
ecological niches | 7 |
infectious compartment | 7 |
field gel | 7 |
old chickens | 7 |
immunity threshold | 7 |
enterococcus faecalis | 7 |
many cases | 7 |
performed using | 7 |
modelling framework | 7 |
will die | 7 |
endemic regions | 7 |
neonatal infections | 7 |
human behavior | 7 |
antibiotics tested | 7 |
weather events | 7 |
private practice | 7 |
serum concentration | 7 |
spongiform encephalopathy | 7 |
cohort study | 7 |
national institutes | 7 |
urine isolates | 7 |
mrsa strains | 7 |
plasma concentrations | 7 |
common cold | 7 |
central nervous | 7 |
bacillary dysentery | 7 |
cases occurred | 7 |
host cells | 7 |
higher levels | 7 |
clinical practice | 7 |
confirmed case | 7 |
nervous system | 7 |
model using | 7 |
adult patients | 7 |
inhibitory concentration | 7 |
wild animals | 7 |
contagious diseases | 7 |
three strains | 7 |
newcastle disease | 7 |
infection rate | 7 |
patients receiving | 7 |
hospital admissions | 7 |
monte carlo | 7 |
doubling time | 7 |
cellular automata | 7 |
cell wall | 7 |
space models | 7 |
contact rates | 7 |
seasonal influenza | 7 |
health measures | 7 |
urine samples | 7 |
natural reservoir | 7 |
attenuated vaccines | 7 |
aureus isolates | 7 |
based model | 7 |
significant increase | 7 |
clinical efficacy | 7 |
mg bid | 7 |
early stages | 7 |
blood cells | 7 |
global level | 7 |
producing strains | 7 |
germany purpose | 7 |
well established | 7 |
marrow transplantation | 7 |
case report | 7 |
communicable disease | 7 |
will lead | 7 |
molecular biology | 7 |
pathological changes | 7 |
cases per | 7 |
chronic hcv | 7 |
acquired immune | 7 |
one week | 7 |
saudi arabia | 7 |
anaerobic bacteria | 7 |
diseases society | 7 |
leading causes | 7 |
geographic range | 7 |
thematic series | 7 |
response system | 7 |
epidemic models | 7 |
cell culture | 7 |
hbv infection | 7 |
sars outbreak | 7 |
general practitioners | 7 |
blood transfusion | 7 |
candida albicans | 7 |
imported cases | 7 |
foodborne outbreaks | 7 |
four patients | 7 |
domestic fowl | 7 |
cumulative number | 7 |
antibiotic resistant | 7 |
global change | 7 |
global infectious | 7 |
wild animal | 7 |
geographical distribution | 7 |
increased susceptibility | 7 |
ecological niche | 7 |
cases increased | 7 |
maximum likelihood | 7 |
first step | 7 |
machine learning | 7 |
petri dish | 7 |
efflux pumps | 7 |
life cycle | 7 |
acquired immunodeficiency | 7 |
adaptive neuro | 7 |
starting point | 7 |
health issues | 7 |
icu patients | 7 |
population biology | 6 |
virus isolation | 6 |
aspergillus fumigatus | 6 |
discrete time | 6 |
cotton wool | 6 |
gene sequencing | 6 |
ct scan | 6 |
ecological communities | 6 |
healthy individuals | 6 |
anthrax spores | 6 |
using data | 6 |
cell activity | 6 |
peptic ulcer | 6 |
widespread use | 6 |
variant strains | 6 |
review board | 6 |
human genome | 6 |
food security | 6 |
confirmed infectious | 6 |
medical faculty | 6 |
several decades | 6 |
health system | 6 |
eustachian tube | 6 |
within days | 6 |
head syndrome | 6 |
diseases including | 6 |
disease epidemic | 6 |
acid testing | 6 |
another study | 6 |
resistant acinetobacter | 6 |
diseases date | 6 |
human hosts | 6 |
following infection | 6 |
inhibitory concentrations | 6 |
coronavirus ibv | 6 |
certain diseases | 6 |
causative agents | 6 |
make sure | 6 |
dna sequence | 6 |
one may | 6 |
host species | 6 |
results show | 6 |
animal production | 6 |
may th | 6 |
clinical features | 6 |
negative staphylococci | 6 |
vaccination rates | 6 |
specific antibody | 6 |
inclusion criteria | 6 |
campylobacter jejuni | 6 |
enhanced surveillance | 6 |
laboratory tests | 6 |
ordinary differential | 6 |
synaptic weights | 6 |
emergency response | 6 |
current slr | 6 |
genome sequencing | 6 |
anthony fauci | 6 |
young chickens | 6 |
difficile infection | 6 |
multicenter study | 6 |
abdominal pain | 6 |
febrile neutropenic | 6 |
antimicrobial treatment | 6 |
pediatric research | 6 |
female mosquito | 6 |
ui ml | 6 |
stenotrophomonas maltophilia | 6 |
regional environmental | 6 |
patients admitted | 6 |
general population | 6 |
human factors | 6 |
health status | 6 |
prediction uncertainty | 6 |
innate immunity | 6 |
observed therapy | 6 |
infectious bursal | 6 |
critical importance | 6 |
bursal disease | 6 |
corona virus | 6 |
swollen head | 6 |
global food | 6 |
initial treatment | 6 |
patients suffering | 6 |
smallpox vaccine | 6 |
internal thiols | 6 |
aedes albopictus | 6 |
infections due | 6 |
emergency physician | 6 |
risk prediction | 6 |
almost certainly | 6 |
chickens following | 6 |
smallpox eradication | 6 |
bronchitis coronavirus | 6 |
different ages | 6 |
cells ml | 6 |
pulmonary syndrome | 6 |
mycoplasma synoviae | 6 |
although ibv | 6 |
received mg | 6 |
antibiotic prophylaxis | 6 |
community ecology | 6 |
fuzzy methods | 6 |
nk cell | 6 |
specific antibodies | 6 |
international institutions | 6 |
total hcv | 6 |
progress towards | 6 |
significant impact | 6 |
maladies infectieuses | 6 |
medical tourism | 6 |
years old | 6 |
food supply | 6 |
diseases may | 6 |
gap analysis | 6 |
ethical issues | 6 |
antibiotic regimen | 6 |
electron microscopy | 6 |
white blood | 6 |
waterborne diseases | 6 |
lachrymal fluid | 6 |
higher risk | 6 |
hazardous waste | 6 |
outpatient treatment | 6 |
recurrent neural | 6 |
coronavirus disease | 6 |
single case | 6 |
contact tracing | 6 |
vector species | 6 |
live infectious | 6 |
control efforts | 6 |
old chicks | 6 |
clinical diagnosis | 6 |
antiviral activity | 6 |
virus replication | 6 |
endemic countries | 6 |
neural networks | 6 |
hiv disease | 6 |
clinical response | 6 |
acute exacerbation | 6 |
statistical inference | 6 |
give rise | 6 |
borne pathogens | 6 |
health workers | 6 |
starting value | 6 |
postexposure prophylaxis | 6 |
related adverse | 6 |
disease evolution | 6 |
elderly patients | 6 |
acid sequence | 6 |
certain time | 6 |
warning systems | 6 |
diseases like | 6 |
new data | 6 |
logistic regression | 6 |
health agencies | 6 |
research agenda | 6 |
positive strains | 6 |
european union | 6 |
acute otitis | 6 |
bronchial secretions | 6 |
many studies | 6 |
clinically relevant | 6 |
go back | 6 |
rapid response | 6 |
flood affected | 6 |
single oral | 6 |
microbiology laboratory | 6 |
acid sequences | 6 |
robert koch | 6 |
clinical presentation | 6 |
hiv transmission | 6 |
dna sequences | 6 |
systems biology | 6 |
specific infectious | 6 |
south america | 6 |
health community | 6 |
treated patients | 6 |
high dose | 6 |
mapping efforts | 6 |
comparative study | 6 |
vibrio vulnificus | 6 |
multidrug resistant | 6 |
new antibiotic | 6 |
medical examiner | 6 |
nalidixic acid | 6 |
dose chemotherapy | 6 |
sampling schemes | 6 |
data available | 6 |
large scale | 6 |
care centers | 6 |
age years | 6 |
physical examination | 6 |
international community | 6 |
proposed framework | 6 |
diffusion test | 6 |
bovine spongiform | 6 |
health regulations | 6 |
specific diseases | 6 |
handling highly | 6 |
health services | 6 |
predictive value | 6 |
wound infections | 6 |
neighbouring cells | 6 |
gram negative | 6 |
host range | 6 |
highly pathogenic | 6 |
currently infected | 6 |
stool samples | 6 |
white house | 6 |
influenzae biogroup | 6 |
infections caused | 6 |
patients years | 6 |
level resistance | 6 |
human life | 6 |
animal contact | 6 |
zone sizes | 6 |
case definition | 6 |
global warming | 6 |
ecological changes | 6 |
commons licence | 6 |
hcv ag | 6 |
associated pneumonia | 6 |
three different | 6 |
case detection | 6 |
us surgeon | 6 |
food items | 6 |
democratic republic | 6 |
hantavirus pulmonary | 6 |
removed cases | 6 |
many countries | 6 |
mediated immune | 6 |
four times | 6 |
will need | 6 |
streptococcal infections | 6 |
reporting system | 6 |
white leghorn | 6 |
will become | 6 |
patient care | 6 |
latent process | 6 |
nile fever | 6 |
great britain | 6 |
human herpesvirus | 6 |
food demand | 6 |
endemic areas | 6 |
care workers | 6 |
maternal antibodies | 6 |
two decades | 6 |
month period | 6 |
feeding billion | 6 |
days post | 6 |
immunosorbent assay | 6 |
economic growth | 6 |
may spread | 6 |
medical academy | 6 |
animal reservoirs | 6 |
human immune | 6 |
infectious person | 6 |
biogroup aegyptius | 6 |
weight loss | 6 |
mg day | 6 |
niche modeling | 6 |
care settings | 5 |
tracheal epithelium | 5 |
vaccinated chickens | 5 |
oral administration | 5 |
high prevalence | 5 |
available surveillance | 5 |
respiratory diseases | 5 |
interactions among | 5 |
disease response | 5 |
vulnerable populations | 5 |
daily dose | 5 |
virus strain | 5 |
clinical specimens | 5 |
lamina propria | 5 |
spatial patterns | 5 |
local public | 5 |
diseases within | 5 |
former yugoslav | 5 |
chlamydia pneumoniae | 5 |
certain strains | 5 |
regression analysis | 5 |
biogeographically complex | 5 |
also increased | 5 |
per patient | 5 |
etiologic agents | 5 |
important infectious | 5 |
national level | 5 |
reproduction numbers | 5 |
susceptible hosts | 5 |
important cause | 5 |
pappas ga | 5 |
new disease | 5 |
recovered cases | 5 |
hazards approach | 5 |
different time | 5 |
resistant strain | 5 |
respiratory pathogens | 5 |
immunization coverage | 5 |
cause infectious | 5 |
central venous | 5 |
ng ml | 5 |
animal hosts | 5 |
host immune | 5 |
year per | 5 |
anterior uveitis | 5 |
new oral | 5 |
deficiency syndrome | 5 |
latent period | 5 |
crinion hofstad | 5 |
episodes per | 5 |
severe cases | 5 |
disease assemblages | 5 |
tissue infections | 5 |
geographic area | 5 |
asct patients | 5 |
osteoarticular involvement | 5 |
outbreak detection | 5 |
acute sinusitis | 5 |
log ui | 5 |
health resources | 5 |
also showed | 5 |
may help | 5 |
disease threat | 5 |
resistant staphylococci | 5 |
spatially explicit | 5 |
meningococcal disease | 5 |
short course | 5 |
significant reduction | 5 |
disease burden | 5 |
auc mic | 5 |
transmitted diseases | 5 |
nearly million | 5 |
commercial airline | 5 |
first group | 5 |
pandemic spread | 5 |
clinical illness | 5 |
incidence rate | 5 |
epidemiological features | 5 |
historical level | 5 |
data obtained | 5 |
diarrheal illnesses | 5 |
data may | 5 |
acinetobacter baumanii | 5 |
critical role | 5 |
infectious origin | 5 |
significantly reduced | 5 |
electronic health | 5 |
yugoslav republic | 5 |
tertiary care | 5 |
one hand | 5 |
transmission occurs | 5 |
renal function | 5 |
across borders | 5 |
lumbar spine | 5 |
first recognized | 5 |
may develop | 5 |
findings suggest | 5 |
mortality due | 5 |
evaluation procedures | 5 |
pneumonic plague | 5 |
experimental infection | 5 |
rapidly evolving | 5 |
complex systems | 5 |
newer fluoroquinolones | 5 |
needle loop | 5 |
work together | 5 |
pharmaceutical industry | 5 |
community protection | 5 |
recent studies | 5 |
artificial neural | 5 |
medical treatment | 5 |
one example | 5 |
viral loads | 5 |
natural host | 5 |
indirect transmission | 5 |
acinetobacter baumannii | 5 |
respiratory secretions | 5 |
microbiology department | 5 |
oral dose | 5 |
poisson process | 5 |
simulation results | 5 |
posttherapeutic pain | 5 |
less effective | 5 |
invasive species | 5 |
compatible clinical | 5 |
deaths occurring | 5 |
surface water | 5 |
conventional methods | 5 |
empirical therapy | 5 |
host will | 5 |
poor sanitation | 5 |
michigan data | 5 |
supercourse asia | 5 |
underlying diseases | 5 |
natural ecosystems | 5 |
african ebola | 5 |
falciparum malaria | 5 |
per capita | 5 |
cytomegalovirus infection | 5 |
surveillance center | 5 |
american board | 5 |
humoral immune | 5 |
immune cell | 5 |
antibody compartment | 5 |
care sector | 5 |
global population | 5 |
global perspective | 5 |
infected person | 5 |
fuzzy set | 5 |
lymphatic filariasis | 5 |
pilot study | 5 |
wild type | 5 |
widely disseminated | 5 |
herbal extracts | 5 |
cholera cases | 5 |
executive order | 5 |
human history | 5 |
resistant tuberculosis | 5 |
urinary excretion | 5 |
bile fluid | 5 |
phylogenetic tree | 5 |
resistance patterns | 5 |
ill health | 5 |
aids pandemic | 5 |
response network | 5 |
diagnostic tests | 5 |
negative bacilli | 5 |
empirical treatment | 5 |
three decades | 5 |
clinical characteristics | 5 |
prion disease | 5 |
first reported | 5 |
inactivated vaccines | 5 |
decision support | 5 |
role played | 5 |
positive culture | 5 |
specific cd | 5 |
patients developed | 5 |
liver disease | 5 |
office involvement | 5 |
ibv variants | 5 |
ulcer disease | 5 |
fact sheet | 5 |
learning rate | 5 |
bottle tube | 5 |
endemic diseases | 5 |
health intelligence | 5 |
trimethoprim sulfamethoxazole | 5 |
dengue transmission | 5 |
rand corporation | 5 |
research institute | 5 |
infection among | 5 |
economic factors | 5 |
hiv patients | 5 |
infectious organisms | 5 |
varies greatly | 5 |
will emerge | 5 |
malaria control | 5 |
aids epidemic | 5 |
vertical transmission | 5 |
nosocomial pneumonia | 5 |
aggregate data | 5 |
laryngeal diphtheria | 5 |
summary statistics | 5 |
individual cases | 5 |
chronic disease | 5 |
disease cases | 5 |
currently available | 5 |
oxide synthase | 5 |
early years | 5 |
national health | 5 |
infectious dose | 5 |
infection may | 5 |
veterinary science | 5 |
enterobacter cloacae | 5 |
nccls recommendations | 5 |
human infection | 5 |
tissue tropisms | 5 |
contaminated food | 5 |
tissue tropism | 5 |
twice daily | 5 |
population will | 5 |
infectious will | 5 |
sismanoglio general | 5 |
acute pharyngitis | 5 |
one strain | 5 |
based haart | 5 |
tract macrophages | 5 |
fluoroquinolone prophylaxis | 5 |
large proportion | 5 |
one month | 5 |
complex diseases | 5 |
global environmental | 5 |
disease physician | 5 |
starting values | 5 |
persistent diarrhea | 5 |
flood event | 5 |
virus strains | 5 |
strongly recommended | 5 |
aps president | 5 |
bacterial pathogens | 5 |
haart era | 5 |
tropical regions | 5 |
less likely | 5 |
enteric rods | 5 |
chronic liver | 5 |
active tuberculosis | 5 |
mucosal immune | 5 |
quarantine compartment | 5 |
nosocomial bloodstream | 5 |
future infectious | 5 |
chronic diarrhea | 5 |
excellent activity | 5 |
monoclonal antibodies | 5 |
research questions | 5 |
model will | 5 |
trench fever | 5 |
significant risk | 5 |
intermediate host | 5 |
certain ibv | 5 |
funeral home | 5 |
chicken lines | 5 |
western hemisphere | 5 |
inducible nitric | 5 |
virulence factors | 5 |
ciprofloxacin resistant | 5 |
different serotypes | 5 |
several days | 5 |
randomized controlled | 5 |
mrsa isolates | 5 |
million cases | 5 |
cellular immune | 5 |
geographical information | 5 |
clinical studies | 5 |
child health | 5 |
colony counts | 5 |
third generation | 5 |
rapidly increasing | 5 |
care providers | 5 |
three compartments | 5 |
pediatric text | 5 |
biological attack | 5 |
biodiversity loss | 5 |
bactericidal effect | 5 |
certain infectious | 5 |
amoxicillin clavulanate | 5 |
positive patients | 5 |
health communities | 5 |
linked immunosorbent | 5 |
airborne transmission | 5 |
rapid diagnosis | 5 |
body weight | 5 |
institutional review | 5 |
zoonotic transmission | 5 |
viral disease | 5 |
new strains | 5 |
university school | 5 |
bronchitis vaccine | 5 |
randomized trial | 5 |
six cases | 5 |
leghorn chickens | 5 |
jones jordan | 5 |
study found | 5 |
human schistosomiasis | 5 |
new antimicrobial | 5 |
land cover | 5 |
septic shock | 5 |
health benefits | 5 |
weeks later | 5 |
results indicate | 5 |
although many | 5 |
control activities | 5 |
severe infections | 5 |
gen cephalosporin | 5 |
interested parties | 5 |
significantly lower | 5 |
american academy | 5 |
research efforts | 5 |
poland purpose | 5 |
takes place | 5 |
amoxicillin clavulanic | 5 |
emergence events | 5 |
wound swabs | 5 |
food hygiene | 5 |
large cities | 5 |
rheumatic heart | 5 |
human pathogen | 5 |
first identified | 5 |
combination therapy | 5 |
reliable data | 5 |
immune suppression | 5 |
detection rate | 5 |
guinea pig | 5 |
plasma hiv | 5 |
constructed using | 5 |
passive case | 5 |
address highly | 5 |
aventis pharma | 5 |
undergoing hematopoietic | 5 |
fungal superinfection | 5 |
differential time | 5 |
general public | 5 |
ward bed | 5 |
central line | 5 |
hemorrhagic fevers | 5 |
immunodeficiency syndrome | 5 |
based models | 5 |
treatment plants | 5 |
clear whether | 5 |
nucleoside analogues | 5 |
infection prevention | 5 |
research center | 5 |
supply chains | 5 |
care facilities | 5 |
national science | 5 |
japanese encephalitis | 5 |
marburg virus | 5 |
zoster virus | 5 |
dependent enhancement | 5 |
pathological manifestations | 5 |
high rates | 5 |
reservoir hosts | 5 |
two algorithms | 5 |
uncomplicated cases | 5 |
ear exudate | 5 |
respiratory infection | 5 |
presumptive place | 5 |
years later | 5 |
epidemiological surveillance | 5 |
human remains | 5 |
city hospital | 5 |
scale processes | 5 |
health management | 5 |
foodborne disease | 5 |
congenital syphilis | 5 |
network model | 5 |
average number | 5 |
mic values | 5 |
disease will | 5 |
virus titres | 5 |
medical sciences | 5 |
proteus mirabilis | 5 |
effective treatment | 5 |
standard antifungal | 5 |
histological changes | 5 |
two weeks | 5 |
cfu biofilm | 5 |
rna levels | 5 |
staphylococcus epidermidis | 5 |
oral streptogramin | 5 |
remote sensing | 5 |
specific immunity | 5 |
cellular automaton | 5 |
markov chain | 5 |
common causes | 5 |
acquired infections | 5 |
will likely | 5 |
food supplies | 5 |
specific pcr | 5 |
prior distributions | 5 |
clinical care | 5 |
acute hepatitis | 5 |
aseptic technique | 5 |
people will | 5 |
underlying conditions | 5 |
different species | 5 |
foodborne outbreak | 5 |
death care | 5 |
associated diarrhoea | 5 |
log cfu | 5 |
rockefeller foundation | 5 |
culture positive | 5 |
antifungal prophylaxis | 5 |
affected people | 5 |
infectious individuals | 5 |
new drugs | 5 |
decision making | 5 |
cure rates | 5 |
causative organisms | 5 |
agricultural practices | 5 |
enterobacter spp | 5 |
fungal strains | 5 |
host susceptibility | 5 |
african countries | 5 |
large part | 5 |
care systems | 5 |
caecal tonsils | 5 |
hiv rna | 5 |
five gram | 5 |
systems ecology | 5 |
resistance among | 5 |
specific immune | 5 |
surgical site | 4 |
zoonotic infectious | 4 |
susceptible individual | 4 |
hcv infection | 4 |
patients older | 4 |
infections may | 4 |
basic research | 4 |
industrialized nations | 4 |
swab specimens | 4 |
model fitting | 4 |
selective pressure | 4 |
interferon induction | 4 |
varying transmission | 4 |
infectious scenarios | 4 |
general medical | 4 |
issue early | 4 |
web based | 4 |
ignjatovic galli | 4 |
possible role | 4 |
highly active | 4 |
may still | 4 |
flu vaccine | 4 |
malaria eradication | 4 |
respiratory syncytial | 4 |
across different | 4 |
perpetual challenge | 4 |
annual deaths | 4 |
significantly associated | 4 |
potential conflicts | 4 |
enterococcus faecium | 4 |
care beds | 4 |
population displacement | 4 |
adult medicine | 4 |
pathogenic microorganisms | 4 |
calcutta university | 4 |
flood disasters | 4 |
wide spectrum | 4 |
adverse reaction | 4 |
th centuries | 4 |
surgical mask | 4 |
deadly disease | 4 |
salad bars | 4 |
contact investigation | 4 |
major source | 4 |
greater risk | 4 |
pediatric age | 4 |
dengue epidemic | 4 |
rate among | 4 |
serological surveys | 4 |
also useful | 4 |
case management | 4 |
unplanned urbanization | 4 |
industrial world | 4 |
week later | 4 |
children compared | 4 |
health threat | 4 |
cd cells | 4 |
population immunity | 4 |
persons concerned | 4 |
id control | 4 |
protection induced | 4 |
rate modifier | 4 |
poverty traps | 4 |
clinical course | 4 |
might lead | 4 |
novel coronavirus | 4 |
birth defects | 4 |
higher latitudes | 4 |
red book | 4 |
randomized clinical | 4 |
tuberculosis patients | 4 |
antibiotics may | 4 |
tyvek suit | 4 |
i must | 4 |
initial antibiotic | 4 |
diseases associated | 4 |
will increase | 4 |
empiric therapy | 4 |
mosquito vectors | 4 |
informed consent | 4 |
pneumoniae strains | 4 |
nasal airway | 4 |
black death | 4 |
infant diarrhea | 4 |
important issue | 4 |
bacterial meningitis | 4 |
studies showed | 4 |
imipenem cilastatin | 4 |
may become | 4 |
oral bacteria | 4 |
ibv serotypes | 4 |
effective prevention | 4 |
infectious pathogens | 4 |
sampling scheme | 4 |
molecular techniques | 4 |
diseases caused | 4 |
another important | 4 |
clinical effect | 4 |
currently unknown | 4 |
effective vaccine | 4 |
joshua lederberg | 4 |
bovine tuberculosis | 4 |
seasonal fluctuations | 4 |
old infectious | 4 |
model consists | 4 |
disease stages | 4 |
cause reproductive | 4 |
four cases | 4 |
insect vectors | 4 |
descriptive epidemiology | 4 |
risk population | 4 |
cell count | 4 |
via blood | 4 |
well documented | 4 |
whose incidence | 4 |
specific th | 4 |
contagious individual | 4 |
among clinical | 4 |
social media | 4 |
laboratory testing | 4 |
two strains | 4 |
epidemiological study | 4 |
different methods | 4 |
disease group | 4 |
another example | 4 |
safe milk | 4 |
also found | 4 |
disease progression | 4 |
immune cells | 4 |
extinction rates | 4 |
rickettsia typhi | 4 |
annual meeting | 4 |
primary resistance | 4 |
ecosystem services | 4 |
environmental changes | 4 |
serosal fluid | 4 |
mucous membranes | 4 |
data collected | 4 |
potential transmission | 4 |
million children | 4 |
ciprofloxacin resistance | 4 |
face shield | 4 |
los angeles | 4 |
new interventions | 4 |
gene transfer | 4 |
particularly important | 4 |
discrete times | 4 |
pneumococcal isolates | 4 |
mmr vaccination | 4 |
evidence suggests | 4 |
rd gen | 4 |
smear positive | 4 |
symptomatic care | 4 |
three major | 4 |
respiratory symptoms | 4 |
twentieth century | 4 |
artificial intelligence | 4 |
care patients | 4 |
antimicrobial activity | 4 |
medical research | 4 |
fever cases | 4 |
general condition | 4 |
significant challenges | 4 |
global human | 4 |
often fatal | 4 |
cyclospora cayetanensis | 4 |
passive surveillance | 4 |
poultry meat | 4 |
positive test | 4 |
chronic recurrent | 4 |
local governments | 4 |
clear advantage | 4 |
baby chicks | 4 |
developed countries | 4 |
moraxella catarrhalis | 4 |
pathogenic organisms | 4 |
epidemic data | 4 |
towards new | 4 |
vesicoureteral reflux | 4 |
immune organs | 4 |
mycoplasma gallisepticum | 4 |
many examples | 4 |
rural infrastructure | 4 |
drug users | 4 |
food industry | 4 |
positive pathogens | 4 |
susceptibility pattern | 4 |
water resources | 4 |
various infectious | 4 |
infect dis | 4 |
kg versus | 4 |
storage areas | 4 |
acute infection | 4 |
state medical | 4 |
unknown origin | 4 |
following section | 4 |
knowledge base | 4 |
horse blood | 4 |
lamblia infection | 4 |
infective endocarditis | 4 |
major international | 4 |
predictive values | 4 |
na resistant | 4 |
infecting agents | 4 |
via complement | 4 |
syncytial virus | 4 |
maintenance therapy | 4 |
population ecology | 4 |
high serological | 4 |
water treatment | 4 |
nephropathogenic infectious | 4 |
private sector | 4 |
geographical areas | 4 |
median ubts | 4 |
microbiology laboratories | 4 |
institut pasteur | 4 |
phase variation | 4 |
like virus | 4 |
vast majority | 4 |
similar results | 4 |
vancomycin resistant | 4 |
eye protection | 4 |
diagnostic procedures | 4 |
cell responses | 4 |
pectoral muscles | 4 |
information system | 4 |
intravenous drug | 4 |
mean sd | 4 |
nine strains | 4 |
ampicillin sulbactam | 4 |
sair model | 4 |
aseptic meningitis | 4 |
target parameters | 4 |
developed world | 4 |
foodborne diseases | 4 |
secondary transmission | 4 |
six months | 4 |
host cell | 4 |
three million | 4 |
two methods | 4 |
disease mitigation | 4 |
surveillance programs | 4 |
near future | 4 |
disease within | 4 |
antigenic changes | 4 |
turning point | 4 |
zoster vaccine | 4 |
tuberculous meningitis | 4 |
last year | 4 |
relevant articles | 4 |
antibacterial effect | 4 |
medical community | 4 |
active immunization | 4 |
seven strains | 4 |
postpartum endometritis | 4 |
virus using | 4 |
indirect effects | 4 |
microbiological analysis | 4 |
cip mic | 4 |
hcv treatment | 4 |
european countries | 4 |
enterotropic strain | 4 |
malaria transmission | 4 |
information gaps | 4 |
analysis showed | 4 |
strains tested | 4 |
herpes viruses | 4 |
spatial distribution | 4 |
geographic information | 4 |
ex vivo | 4 |
monitoring system | 4 |
diphtheria antitoxin | 4 |
fundamental role | 4 |
urban areas | 4 |
haematological malignancies | 4 |
biomed central | 4 |
sensitive line | 4 |
rates among | 4 |
new hosts | 4 |
sectional study | 4 |
hcv genotype | 4 |
health emergency | 4 |
oral therapy | 4 |
new host | 4 |
must decrease | 4 |
hospital settings | 4 |
years earlier | 4 |
supercourse lectures | 4 |
physical environmental | 4 |
prospective observational | 4 |
water supplies | 4 |
virus infectious | 4 |
help us | 4 |
kaposi sarcoma | 4 |
genetic variability | 4 |
past history | 4 |
social determinants | 4 |
summer months | 4 |
digital immune | 4 |
neisseria meningitidis | 4 |
microbial world | 4 |
thorough understanding | 4 |
global pandemic | 4 |
information analysis | 4 |
health control | 4 |
future studies | 4 |
soviet union | 4 |
success story | 4 |
biogeographic patterns | 4 |
new global | 4 |
urban slums | 4 |
wound infection | 4 |
common cause | 4 |
salmonella enteritidis | 4 |
antibiotic consumption | 4 |
randomly selected | 4 |
day care | 4 |
natural resources | 4 |
preventive medicine | 4 |
tropical forests | 4 |
lysis via | 4 |
antigen assay | 4 |
warning signals | 4 |
model equation | 4 |
cases reported | 4 |
highest risk | 4 |
natural systems | 4 |
living organisms | 4 |
death rates | 4 |
new ecological | 4 |
media containing | 4 |
public spending | 4 |
joint pain | 4 |
also determined | 4 |
antimicrobial drugs | 4 |
strain victoria | 4 |
may even | 4 |
legionella pneumophila | 4 |
sputum specimens | 4 |
important problem | 4 |
notifiable infectious | 4 |
hiv infections | 4 |
aerosol transmission | 4 |
per publication | 4 |
nearly billion | 4 |
isolated salmonellae | 4 |
arthropod vector | 4 |
affected countries | 4 |
resistant streptococcus | 4 |
safe water | 4 |
potential impact | 4 |
special reference | 4 |
invariably fatal | 4 |
table provides | 4 |
healthy adult | 4 |
bacterial ie | 4 |
antibacterial agents | 4 |
diseases occur | 4 |
authors declare | 4 |
africa ebola | 4 |
increased frequency | 4 |
pneumocystis carinii | 4 |
human existence | 4 |
much better | 4 |
quinolone resistance | 4 |
seven hundred | 4 |
response systems | 4 |
reference strain | 4 |
endemic area | 4 |
mechanical ventilation | 4 |
like strains | 4 |
poor countries | 4 |
zoonotic reservoirs | 4 |
commons attribution | 4 |
chronic bronchitis | 4 |
confidence interval | 4 |
resistance mechanisms | 4 |
case numbers | 4 |
pediatric infections | 4 |
nile infection | 4 |
habitat fragmentation | 4 |
young chicks | 4 |
single scaler | 4 |
emerging zoonotic | 4 |
epidemiologic transition | 4 |
positive cocci | 4 |
bacterial isolates | 4 |
warning signal | 4 |
bacteria resistant | 4 |
significantly related | 4 |
virulence genes | 4 |
infectious laryngotracheitis | 4 |
vn tests | 4 |
section will | 4 |
often associated | 4 |
one way | 4 |
bioterrorist attack | 4 |
diseases might | 4 |
hgv infection | 4 |
underlying latent | 4 |
undocumented migrants | 4 |
previous antibiotic | 4 |
new technology | 4 |
specific therapy | 4 |
important public | 4 |
infection risk | 4 |
least days | 4 |
streptococcal virulence | 4 |
fecal samples | 4 |
examiner coroner | 4 |
term immunity | 4 |
new england | 4 |
avian viruses | 4 |
suspected case | 4 |
deliberate efforts | 4 |
varicella zoster | 4 |
automated system | 4 |
sex ratio | 4 |
puerto rico | 4 |
standard sir | 4 |
disease modelling | 4 |
sars epidemic | 4 |
molten agar | 4 |
coronavirus infectious | 4 |
common infectious | 4 |
marked differences | 4 |
health personnel | 4 |
diseases spread | 4 |
microscopic examination | 4 |
test results | 4 |
two types | 4 |
certain countries | 4 |
cardiovascular disease | 4 |
influenza mortality | 4 |
new vaccines | 4 |
see table | 4 |
island biogeography | 4 |
biogeographic regionalisation | 4 |
decreased susceptibility | 4 |
mycoses study | 4 |
long periods | 4 |
several years | 4 |
dengue outbreaks | 4 |
affected communes | 4 |
become infectious | 4 |
borrelia burgdorferi | 4 |
following nccls | 4 |
received antibiotics | 4 |
biological vector | 4 |
alt abnormality | 4 |
resistant mrsa | 4 |
exposed compartment | 4 |
first century | 4 |
ibv isolates | 4 |
throughout history | 4 |
aeruginosa strains | 4 |
san francisco | 4 |
marginal strength | 4 |
common source | 4 |
stochastic approximation | 4 |
study period | 4 |
viral hemorrhagic | 4 |
bronchitis vaccines | 4 |
limited number | 4 |
toward commensalism | 4 |
arthropod vectors | 4 |
current status | 4 |
ad hoc | 4 |
might also | 4 |
compartment infectious | 4 |
chickens infectious | 4 |
pathogen spillover | 4 |
medical specialty | 4 |
genome sequence | 4 |
lessons learned | 4 |
college london | 4 |
extreme water | 4 |
european region | 4 |
contributing factors | 4 |
medical geography | 4 |
best practices | 4 |
two million | 4 |
negative pathogens | 4 |
positive cultures | 4 |
care provider | 4 |
health challenges | 4 |
years since | 4 |
wildlife populations | 4 |
past researches | 4 |
cukurova university | 4 |
airline travel | 4 |
clinical hospital | 4 |
received training | 4 |
cellular immunity | 4 |
epidemic disease | 4 |
imipenem use | 4 |
lucio fabricant | 4 |
community acquired | 4 |
war metaphor | 4 |
beta diversity | 4 |
resistant gram | 4 |
population level | 4 |
venous catheter | 4 |
serum levels | 4 |
davelaar kouwenhoven | 4 |
incidence following | 4 |
risk assessments | 4 |
factors affecting | 4 |
sample size | 4 |
sierra leone | 4 |
neutropenic cancer | 4 |
healthcare system | 4 |
hospital care | 4 |
report pm | 4 |
restaurant salad | 4 |
th edn | 4 |
tropical infectious | 4 |
two reviews | 4 |
new epidemic | 4 |
mosquito population | 4 |
serial interval | 4 |
intraocular inflammation | 4 |
early childhood | 4 |
stochastic processes | 4 |
chicken tissues | 4 |
updated guidelines | 4 |
effective risk | 4 |
perform autopsies | 4 |
herpes virus | 4 |
economic conditions | 4 |
three main | 4 |
listeria monocytogenes | 4 |
estimated million | 4 |
acute leukemia | 4 |
pandemic threats | 4 |
parametric function | 4 |
according nccls | 4 |
scaler techniques | 4 |
geographic areas | 4 |
sperm production | 4 |
virus vaccines | 4 |
bronchoalveolar lavage | 4 |
gram stain | 4 |
sars coronavirus | 4 |
line bacteremia | 4 |
hgv rna | 4 |
microbial adaptation | 4 |
much less | 4 |
conditionally independent | 4 |
data model | 4 |
one million | 4 |
humans via | 4 |
tmp smx | 4 |
reduce disease | 4 |
human settlements | 4 |
protective effect | 4 |
extremely low | 4 |
based reporting | 4 |
fungal infection | 4 |
diseases global | 4 |
pneumocystis jirovecii | 4 |
seek medical | 4 |
clinical status | 4 |
killing activity | 4 |
one year | 4 |
emergency department | 4 |
people died | 4 |
fresh water | 4 |
one type | 4 |
environmental health | 4 |
great interest | 4 |
five volumes | 4 |
day ahead | 4 |
included patients | 4 |
human primates | 4 |
vaccinated group | 4 |
observable model | 4 |
risks associated | 4 |
serious cases | 4 |
lung disease | 4 |
significantly reduce | 4 |
pig models | 4 |
culture media | 4 |
multiple species | 4 |
novel method | 4 |
ecological processes | 4 |
gall bladder | 4 |
disease mortality | 4 |
data used | 4 |
variant infectious | 4 |
regional scale | 4 |
deliberately emerging | 4 |
pectoral myopathy | 4 |
survey results | 4 |
plasmodium falciparum | 4 |
several studies | 4 |
semmelweis university | 4 |
hinton agar | 4 |
specific igm | 4 |
species distributions | 4 |
health effects | 4 |
papers presented | 4 |
swine flu | 4 |
group consisted | 4 |
common antibiotics | 4 |
statistical analyses | 4 |
initial conditions | 4 |
cecal tonsils | 4 |
emmett holt | 4 |
cover cap | 4 |
resistant line | 4 |
routine surveillance | 4 |
disease emerging | 4 |
diagnostic techniques | 4 |
local antibody | 4 |
major epidemics | 4 |
patient underwent | 4 |
global travel | 4 |
reverse vaccinology | 4 |
gene segment | 4 |
west african | 4 |
agar diffusion | 4 |
engineering approaches | 4 |
tubular epithelium | 4 |
spatial heterogeneity | 4 |
spain purpose | 4 |
cancer research | 4 |
viral vaccines | 4 |
gm ml | 4 |
killing effect | 4 |
lzd versus | 4 |
electronic supplementary | 4 |
dual infections | 4 |
endemic disease | 4 |
dosing interval | 4 |
mediated immunity | 4 |
influenzae type | 4 |
perspective emerging | 4 |
chagas disease | 4 |
early warnings | 4 |
inward variables | 4 |
acinetobacter spp | 4 |
complex interactions | 4 |
new vaccine | 4 |
clinical success | 4 |
mcmc chains | 4 |
body systems | 4 |
global emerging | 4 |
provide information | 4 |
avian flu | 4 |
blood products | 4 |
respiratory tissues | 4 |
nineteenth century | 4 |
human activities | 4 |
secreting cells | 4 |
surveillance activities | 4 |
least months | 4 |
toxic shock | 4 |
large community | 4 |
influenza infections | 4 |
previous reviews | 4 |
infected human | 4 |
disease mapping | 4 |
nosocomial strains | 4 |
new insights | 4 |
five strains | 4 |
new vulnerability | 4 |
mononuclear cell | 4 |
neonatal tetanus | 4 |
initial condition | 4 |
derived macrophages | 4 |
specific pathogen | 4 |
diagnostic disc | 4 |
sequence data | 4 |
state health | 4 |
one another | 4 |
initial values | 4 |
cells mm | 4 |
social network | 4 |
surveillance network | 4 |
data quality | 4 |
ward beds | 4 |
vaccine safety | 4 |
key features | 4 |
data availability | 4 |
observational study | 4 |
dengue shock | 4 |
antibiotic policy | 4 |
studies assessing | 4 |
developed nations | 4 |
molecular diagnostics | 4 |
frequently isolated | 4 |
preliminary report | 4 |
significantly different | 4 |
including infectious | 4 |
eight strains | 4 |
will require | 4 |
agricultural drivers | 4 |
species isolated | 4 |
increasing trend | 4 |
susceptible strain | 4 |
epidemic model | 4 |
zoonotic influenza | 4 |
day old | 4 |
frequently applied | 4 |
cd count | 4 |
wild birds | 4 |
systematic component | 4 |
timely manner | 4 |
unprecedented rate | 4 |
data source | 4 |
maribor teaching | 4 |
day incubation | 4 |
pediatric aids | 4 |
package esir | 4 |
health problems | 4 |
standardized education | 4 |
community outbreak | 4 |
success rates | 4 |
new macrolides | 4 |
important implications | 4 |
support system | 4 |
bubonic plague | 4 |
differences among | 4 |
prefectural government | 4 |
lumbar puncture | 4 |
sinus cavities | 4 |
modelling study | 4 |
health standpoint | 4 |
infectious mosquito | 4 |
outbreak among | 4 |
live ibv | 4 |
disc synergy | 4 |
national surveillance | 4 |
last decade | 4 |
exponential growth | 4 |
vaccine adjuvants | 4 |
new variant | 4 |
central america | 4 |
temporal patterns | 4 |
dengue viruses | 4 |
approximately million | 4 |
parameter values | 4 |
haemorrhagic fevers | 4 |
antiseptic agents | 4 |
tract pathogens | 4 |
increasing global | 4 |
examined strains | 4 |
materials generated | 4 |
single dose | 4 |
natural habitat | 4 |
alveolar echinococcosis | 4 |
foreign countries | 4 |
handle highly | 4 |
less frequent | 4 |
transmission dynamics | 4 |
local immunity | 4 |
human infections | 4 |
hinder progress | 4 |
cholera infantum | 4 |
green revolution | 4 |
old man | 4 |
bladder tissue | 4 |
serious consequences | 4 |
vaccination campaigns | 4 |
connectivity coefficient | 4 |
diseases emerging | 4 |
adult population | 4 |
epidemiological transition | 4 |
quite different | 4 |
infected persons | 4 |
rpr rpr | 4 |
major public | 4 |
genetic evolution | 4 |
epidemic spread | 4 |
acutely infectious | 4 |
gestational age | 4 |
phase i | 4 |
cited times | 4 |
coli isolated | 4 |
attenuated ib | 4 |
small number | 4 |
laboratory techniques | 4 |
environmental degradation | 4 |
different combinations | 4 |
large numbers | 4 |
persisting fever | 4 |
gates foundation | 4 |
mechanical vector | 4 |
previously described | 4 |
disease severity | 4 |
global development | 4 |
deaths due | 4 |
para alpha | 4 |
ebola epidemic | 4 |
first medical | 4 |
human diseases | 4 |
like receptors | 4 |
reduce infectious | 4 |
schistosomiasis control | 4 |
diseases topics | 4 |
eid events | 4 |
real time | 4 |
main purpose | 4 |
virus vaccine | 4 |
spotted fever | 4 |
increased use | 4 |
infecting agent | 4 |
mm day | 4 |
evaluation techniques | 4 |
composite likelihood | 4 |
resistance determinants | 4 |
infectious state | 4 |
using agar | 4 |
borne viruses | 4 |
food item | 4 |
chong apostolov | 4 |
organisms included | 3 |
epidemiological characteristics | 3 |
delhi metallo | 3 |
included chapters | 3 |
technically speaking | 3 |
second wave | 3 |
latent processes | 3 |
acute myeloid | 3 |
new human | 3 |
health response | 3 |
generally considered | 3 |
peak time | 3 |
ml vs | 3 |
intervention measures | 3 |
remains constant | 3 |
increase disease | 3 |
next years | 3 |
many bacterial | 3 |
gave rise | 3 |
palm civet | 3 |
substantial decline | 3 |
ent disorders | 3 |
parameter identifiability | 3 |
increased rodent | 3 |
antimicrobial agent | 3 |
winter months | 3 |
tropical disease | 3 |
economic burden | 3 |
clinopodiodes lam | 3 |
bacterial strains | 3 |
brazilian purpuric | 3 |
antibiotic efficacy | 3 |
immunocompetent patients | 3 |
gut tissues | 3 |
resistant mutant | 3 |
transport fluid | 3 |
next pandemic | 3 |
fixed values | 3 |
laboratory parameters | 3 |
postoperative wound | 3 |
week old | 3 |
infectious i | 3 |
model based | 3 |
limited consequences | 3 |
medical wastes | 3 |
disease outcomes | 3 |
fungal diseases | 3 |
health metrics | 3 |
software program | 3 |
may involve | 3 |
receiver operating | 3 |
major categories | 3 |
minimal inhibitory | 3 |
mass vaccination | 3 |
dastidar sg | 3 |
death data | 3 |
tuberculosis control | 3 |
scientific meeting | 3 |
crimean haemorrhagic | 3 |
spread patterns | 3 |
earlier days | 3 |
epidemic intensity | 3 |
multiple myeloma | 3 |
real data | 3 |
infection transmitted | 3 |
serological evidence | 3 |
molecular methods | 3 |
clinical description | 3 |